<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sona Nanotech Inc — News on 6ix</title>
<link>https://6ix.com/company/sona-nanotech-inc</link>
<description>Latest news and press releases for Sona Nanotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sona-nanotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683683f478dffbe2df1697d0.webp</url>
<title>Sona Nanotech Inc</title>
<link>https://6ix.com/company/sona-nanotech-inc</link>
</image>
<item>
<title>Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-showcases-cancer-therapy-results-at-prestigious-industry-cancer-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-showcases-cancer-therapy-results-at-prestigious-industry-cancer-conferences</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona's data at the American Society of Clinical Oncology ("ASCO") annual meeting May 29 – June 2, 2026, a confe</description>
</item>
<item>
<title>Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-appointment-of-two-leading-oncologists-to-its-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-appointment-of-two-leading-oncologists-to-its-scientific-advisory-board</guid>
<pubDate>Thu, 16 Apr 2026 10:30:00 GMT</pubDate>
<description>Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is honoured to announce the appointment of two renowned oncologists to its scientific advisory board: Dr. Michael Smylie and Dr. Jonathan Trites.</description>
</item>
<item>
<title>Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-clinical-cancer-study-tissue-analysis-confirms-tumor-priming-and-suggests-potential-immunotherapy-synergies</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-clinical-cancer-study-tissue-analysis-confirms-tumor-priming-and-suggests-potential-immunotherapy-synergies</guid>
<pubDate>Mon, 13 Apr 2026 11:29:00 GMT</pubDate>
<description>Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to provide follow-up histology tissue analysis data from its first-in-human early feasibility study of its Targeted Hyperthermia Therapy ('THT') in late stage melanoma patients who had failed on standard immunotherapy protocols (the "Study"). An extensive multiplex histological tissue analysis conducted at Dalhousie University of representative tissues from Study patients showed extensive natural killer cell infilt</description>
</item>
<item>
<title>Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotechs-tht-cancer-therapy-demonstrates-strong-efficacy-and-durability-in-combination-with-immunotherapy-in-peer-reviewed-preclinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotechs-tht-cancer-therapy-demonstrates-strong-efficacy-and-durability-in-combination-with-immunotherapy-in-peer-reviewed-preclinical-study</guid>
<pubDate>Tue, 07 Apr 2026 12:18:00 GMT</pubDate>
<description>Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is excited to announce publication of a preclinical study using its Targeted Hyperthermia Therapy ("THT") to treat cancer, in the Journal of Nanobiotechnology (https://bit.ly/47M2VoQ) which demonstrated treatment durability to the end of the 45 day study period when it was given in combination with immunotherapy. Building on its prior body of preclinical research treating melanoma and breast cancer (as published in Frontiers i</description>
</item>
<item>
<title>Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-to-hold-investor-webinar-to-discuss-follow-up-data-from-first-in-human-cancer-therapy-study</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-to-hold-investor-webinar-to-discuss-follow-up-data-from-first-in-human-cancer-therapy-study</guid>
<pubDate>Mon, 16 Mar 2026 16:24:00 GMT</pubDate>
<description>Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), will host an investor webinar on Wednesday, March 18th at 3:30pm ET to discuss follow-up data from its first-in-human study of its Targeted Hyperthermia Therapy ("THT") (the "Study") that resulted the generation of immune responses in 8/10 treated and biopsied tumors, with complete responses seen in 6/10. Interested parties can register for this webinar via the following link: https://us06web.zoom.us/webinar/register/WN_D93hv</description>
</item>
<item>
<title>Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-reports-80-response-100000237</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-reports-80-response-100000237</guid>
<pubDate>Mon, 20 Oct 2025 10:00:00 GMT</pubDate>
<description>-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within two weeks of initial treatment --Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical study treating patients with histologically confirmed,...</description>
</item>
<item>
<title>Sona Nanotech To Host Investor Webinar To Discuss Clinical Study</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-host-investor-webinar-200400205</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-host-investor-webinar-200400205</guid>
<pubDate>Fri, 17 Oct 2025 20:04:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy treatment were recruited into this early feasibility study. Interested parties can..</description>
</item>
<item>
<title>Sona Provides Update on First-In-Human Clinical Trial</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-provides-first-human-clinical-131400014</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-provides-first-human-clinical-131400014</guid>
<pubDate>Mon, 25 Aug 2025 13:14:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first...</description>
</item>
<item>
<title>Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-announces-canadian-melanoma-clinical-100000567</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-announces-canadian-melanoma-clinical-100000567</guid>
<pubDate>Wed, 23 Jul 2025 10:00:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, has received Nova Scotia Health Research Ethics Board ("REB") approval to conduct its proposed pilot human clinical trial study (the "Pilot Study") of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma pa</description>
</item>
<item>
<title>First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/first-patient-dosed-early-feasibility-131900150</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/first-patient-dosed-early-feasibility-131900150</guid>
<pubDate>Mon, 07 Jul 2025 13:19:00 GMT</pubDate>
<description>Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibilit</description>
</item>
<item>
<title>Sona Announces Ethics Committee Approval For Melanoma Clinical Trial</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-announces-ethics-committee-approval-124500347</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-announces-ethics-committee-approval-124500347</guid>
<pubDate>Fri, 27 Jun 2025 12:45:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment. Sona CEO David Regan commented, "This ethics committ</description>
</item>
<item>
<title>Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-engages-clinical-trial-clinic-122300177</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-engages-clinical-trial-clinic-122300177</guid>
<pubDate>Mon, 16 Jun 2025 12:23:00 GMT</pubDate>
<description>First Patients Expected to be Enrolled This MonthHalifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy ("THT"). Sona has engaged Bradford Hil</description>
</item>
<item>
<title>Sona Successfully Completes FDA-Required Toxicity Study</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-successfully-completes-fda-required-122700756</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-successfully-completes-fda-required-122700756</guid>
<pubDate>Tue, 27 May 2025 12:27:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc. Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, "This study indicates Sona's gold nanorods were well tolerated, with no signs of ...</description>
</item>
<item>
<title>Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-announces-successful-study-showing-133200541</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-announces-successful-study-showing-133200541</guid>
<pubDate>Thu, 15 May 2025 13:32:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.Sona Nanotech CEO, David Regan, commented, "These gr</description>
</item>
<item>
<title>BioVaxys and Sona Nanotech Enter Research Collaboration</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/biovaxys-sona-nanotech-enter-research-131200742</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/biovaxys-sona-nanotech-enter-research-131200742</guid>
<pubDate>Wed, 07 May 2025 13:12:00 GMT</pubDate>
<description>Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a phototherm</description>
</item>
<item>
<title>Sona Nanotech Announces Annual Options Grants</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-annual-options-132100699</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-annual-options-132100699</guid>
<pubDate>Thu, 01 May 2025 13:21:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The ...</description>
</item>
<item>
<title>Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-presents-additional-preclinical-data-124600813</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-presents-additional-preclinical-data-124600813</guid>
<pubDate>Wed, 19 Mar 2025 12:46:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to provide updated data confirming efficacy of its Targeted Hyperthermia Therapy ("THT") cancer treatment in an immunotherapy resistant cancer. In this follow-up data to the previously released preliminary study (see press release dated December 11, 2024), again using an industry-standard, immunotherapy resistant, CT-26 colon cancer model, Sona's THT cancer t</description>
</item>
<item>
<title>Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-inc-ceo-david-123000622</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-inc-ceo-david-123000622</guid>
<pubDate>Thu, 06 Mar 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, NY / ACCESS Newswire / March 6, 2025 / David Regan, CEO of Sona Nanotech Inc. (OTCQB:SNANF)(CSE:SONA), will be presenting at this year's Investor Summit Virtual on March 11th at 11:30am ET. About Sona Nanotech Inc.(OTCQB: SNANF) (CSE: SONA), ...</description>
</item>
<item>
<title>Sona Nanotech Announces Filing of Provisional Patent Application</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-filing-of-provisional-patent-application</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-announces-filing-of-provisional-patent-application</guid>
<pubDate>Mon, 18 Mar 2024 13:21:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB:...</description>
</item>
<item>
<title>Sona Nanotech Grants Options</title>
<link>https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-grants-options</link>
<guid isPermaLink="true">https://6ix.com/company/sona-nanotech-inc/news/sona-nanotech-grants-options</guid>
<pubDate>Fri, 01 Mar 2024 14:03:00 GMT</pubDate>
<description>Halifax, Nova Scotia--(Newsfile Corp. - March 1, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: ...</description>
</item>
</channel>
</rss>